


Application of Pyrrole in Developing Therapeutic Agents

Lead Guest Editor: Francesca Aiello

Guest Editors: Margarita Vega Holm and Anna Ramunno






Application of Pyrrole in Developing Therapeutic Agents

Application of Pyrrole in Developing Therapeutic Agents

Lead Guest Editor: Francesca Aiello

Guest Editors: Margarita Vega Holm and Anna
Ramunno



Copyright © 2021 Hindawi Limited. All rights reserved.


This is a special issue published in "Journal of Chemistry." All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chief Editor

Kaustubha Mohanty, India

Associate Editors

Mohammad Al-Ghouti, Qatar


Tingyue Gu , USA

Teodorico C. Ramalho , Brazil

Artur M. S. Silva , Portugal


Academic Editors

Jinwei Duan, China

Luqman C. Abdullah , Malaysia

Dr Abhilash , India

Amitava Adhikary, USA

Amitava Adhikary , USA

Mozhgan Afshari, Iran

Daryoush Afzali , Iran

Mahmood Ahmed, Pakistan


Islam Al-Akraa , Egypt


Juan D. Alché , Spain

Gomaa A. M. Ali , Egypt

Mohd Sajid Ali , Saudi Arabia

Shafaqat Ali , Pakistan


Patricia E. Allegretti , Argentina

Marco Anni , Italy

Alessandro Arcovito, Italy

Hassan Arida , Saudi Arabia

Umair Ashraf, Pakistan


Narcis Avarvari , France

Davut Avci , Turkey


Chandra Azad , USA

Mohamed Azaroual, France

Rasha Azzam , Egypt


Hassan Azzazy , Egypt

Renal Backov, France

Suresh Kannan Balasingam , Republic of Korea

Sukanta Bar , USA

Florent Barbault , France

Maurizio Barbieri , Italy

James Barker , United Kingdom

Salvatore Barreca , Italy

Jorge Barros-Velázquez , Spain

THANGAGIRI Baskaran , India

Haci Baykara, Ecuador

Michele Benedetti, Italy

Laurent Billon, France

Marek Biziuk, Poland

Jean-Luc Blin , France

Tomislav Bolanca , Croatia

Ankur Bordoloi , India

Cato Brede , Norway


Leonid Breydo , USA


Wybren J. Buma , The Netherlands

J. O. Caceres , Spain


Patrizia Calaminici , Mexico


Claudio Cameselle , Spain

Joaquin Campos , Spain

Dapeng Cao , China

Domenica Capasso , Italy

Stefano Caporali , Italy

Zenilda Cardeal , Brazil

Angela Cardinali , Italy

Stefano Carli , Italy

Maria F. Carvalho , Portugal


Susana Casal , Portugal


David E. Chavez, USA

Riccardo Chelli , Italy

Zhongfang Chen , Puerto Rico

Vladislav Chrastny , Czech Republic

Roberto Comparelli , Italy

Filomena Conforti , Italy

Luca Conti , Italy


Christophe Coquelet, France

Filomena Corbo , Italy

Jose Corchado , Spain

Maria N. D.S. Cordeiro , Portugal

Claudia Crestini, Italy

Gerald Culioli , France

Nguyen Duc Cuong , Vietnam

Stefano D'Errico , Italy


Matthias D'hooghe , Belgium


Samuel B. Dampare, Ghana

Umashankar Das, Canada

Victor David, Romania

Annalisa De Girolamo, Italy


Antonio De Lucas-Consuegra , Spain

Marccone A. L. De Oliveira , Brazil

Paula G. De Pinho , Portugal

Damião De Sousa , Brazil

Francisco Javier Deive , Spain

Tianlong Deng , China

Fatih Deniz , Turkey
Claudio Di Iaconi, Italy
Irene Dini , Italy
Daniele Dondi, Italy
Yingchao Dong , China
Dennis Douroumis , United Kingdom
John Drexler, USA
Qizhen Du, China
Yuanyuan Duan , China
Philippe Dugourd, France
Frederic Dumur , France
Grégory Durand , France
Mehmet E. Duru, Turkey
Takayuki Ebata , Japan
Arturo Espinosa Ferao , Spain
Valdemar Esteves , Portugal
Cristina Femoni , Italy
Gang Feng, China
Dieter Fenske, Germany
Jorge F. Fernandez-Sanchez , Spain
Alberto Figoli , Italy
Elena Forte, Italy
Sylvain Franger , France
Emiliano Fratini , Italy
Franco Frau , Italy
Bartolo Gabriele , Italy
Guillaume Galliero , France
Andrea Gambaro , Italy
Vijay Kumar Garlapati, India
James W. Gauld , Canada
Barbara Gawdzik , Poland
Pier Luigi Gentili , Italy
Beatrice Giannetta , Italy
Dimosthenis L. Giokas , Greece
Alejandro Giorgetti , Italy
Alexandre Giuliani , France
Elena Gomez , Spain
Yves Grohens, France
Katharina Grupp, Germany
Luis F. Guido , Portugal
Maolin Guo, USA
Wenshan Guo , Australia
Leena Gupta , India
Muhammad J. Habib, USA
Jae Ryang Hahn, Republic of Korea

Christopher G. Hamaker , USA
Ashanul Haque , Saudi Arabia
Yusuke Hara, Japan
Naoki Haraguchi, Japan
Serkos A. Haroutounian , Greece
Rudi Hendra , Indonesia
Javier Hernandez-Borges , Spain
Miguel Herrero, Spain
Mark Hoffmann , USA
Hanmin Huang, China
Doina Humelnicu , Romania
Charlotte Hurel, France
Nenad Ignjatović , Serbia
Ales Imramovsky , Czech Republic
Muhammad Jahangir, Pakistan
Philippe Jeandet , France
Sipak Joyasawal, USA
Sławomir M. Kaczmarek, Poland
Ewa Kaczorek, Poland
Mostafa Khajeh, Iran
Srećko I. Kirin , Croatia
Anton Kokalj , Slovenia
Sevgi Kolaylı , Turkey
Takeshi Kondo , Japan
Christos Kordulis, Greece
Ioannis D. Kostas , Greece
Yiannis Kourkoutas , Greece
Henryk Kozłowski, Poland
Yoshihiro Kudo , Japan
Avvaru Praveen Kumar , Ethiopia
Dhanaji Lade, USA
Isabel Lara , Spain
Jolanta N. Latosinska , Poland
João Paulo Leal , Portugal
Woojin Lee, Kazakhstan
Yuan-Pern Lee , Taiwan
Matthias Lein , New Zealand
Huabing Li, China
Jinan Li , USA
Kokhwa Lim , Singapore
Teik-Cheng Lim , Singapore
Jianqiang Liu , China
Xi Liu , China
Xinyong Liu , China
Zhong-Wen Liu , China


Eulogio J. Llorent-Martínez , Spain
Pasquale Longo , Italy
Pablo Lorenzo-Luis , Spain
Zhang-Hui Lu, China
Devanand Luthria, USA
Konstantin V. Luzyanin , United Kingdom
Basavarajaiah S M, India
Mari Maeda-Yamamoto , Japan
Isabel Mafra , Portugal
Dimitris P. Makris , Greece
Pedro M. Mancini, Argentina
Marcelino Maneiro , Spain
Giuseppe F. Mangiatordi , Italy
Casimiro Mantell , Spain
Carlos A Martínez-Huitle , Brazil
José M. G. Martinho , Portugal
Andrea Mastinu , Italy
Cesar Mateo , Spain
Georgios Matthaiolampakis, USA
Mehrab Mehrvar, Canada
Saurabh Mehta , India
Oinam Romesh Meitei , USA
Saima Q. Memon , Pakistan
Morena Miciaccia, Italy
Maurice Millet , France
Angelo Minucci, Italy
Liviu Mitu , Romania
Hideto Miyabe , Japan
Ahmad Mohammad Alakraa , Egypt
Kaustubha Mohanty, India
Subrata Mondal , India
José Morillo, Spain
Giovanni Morrone , Italy
Ahmed Mourran, Germany
Nagaraju Mupparapu , USA
Markus Muschen, USA
Benjamin Mwashote , USA
Mallikarjuna N. Nadagouda , USA
Lutfun Nahar , United Kingdom
Kamala Kanta Nanda , Peru
Senthilkumar Nangan, Thailand
Mu. Naushad , Saudi Arabia
Gabriel Navarrete-Vazquez , Mexico
Jean-Marie Nedelec , France
Sridhar Goud Nerella , USA
Nagatoshi Nishiwaki , Japan
Tzortzis Nomikos , Greece
Beatriz P. P. Oliveira , Portugal
Leonardo Palmisano , Italy
Mohamed Afzal Pasha , India
Dario Pasini , Italy
Angela Patti , Italy
Massimiliano F. Peana , Italy
Andrea Penoni , Italy
Franc Perdih , Slovenia
Jose A. Pereira , Portugal
Pedro Avila Pérez , Mexico
Maria Grazia Perrone , Italy
Silvia Persichilli , Italy
Thijs A. Peters , Norway
Christophe Petit , France
Marinos Pitsikalis , Greece
Rita Rosa Plá, Argentina
Fabio Polticelli , Italy
Josefina Pons, Spain
V. Prakash Reddy , USA
Thathan Premkumar, Republic of Korea
Maciej Przybyłek , Poland
María Quesada-Moreno , Germany
Maurizio Quinto , Italy
Franck Rabilloud , France
C.R. Raj, India
Sanchayita Rajkhowa , India
Manzoor Rather , India
Enrico Ravera , Italy
Julia Revuelta , Spain
Muhammad Rizwan , Pakistan
Manfredi Rizzo , Italy
Maria P. Robalo , Portugal
Maria Roca , Spain
Nicolas Roche , France
Samuel Rokhum , India
Roberto Romeo , Italy
Antonio M. Romerosa-Nievas , Spain
Arpita Roy , India
Eloy S. Sanz P rez , Spain
Nagaraju Sakkani , USA
Diego Sampedro , Spain
Shengmin Sang , USA

Vikram Sarpe , USA
Adrian Saura-Sanmartin , Spain
Stéphanie Sayen, France
Ewa Schab-Balcerzak , Poland
Hartwig Schulz, Germany
Gulaim A. Seisenbaeva , Sweden
Serkan Selli , Turkey
Murat Senturk , Turkey
Beatrice Severino , Italy
Sunil Shah Shah , USA
Ashutosh Sharma , USA
Hideaki Shirota , Japan
Cláudia G. Silva , Portugal
Ajaya Kumar Singh , India
Vijay Siripuram, USA
Ponnurengam Malliappan Sivakumar ,
Japan
Tomás Sobrino , Spain
Raquel G. Soengas , Spain
Yujiang Song , China
Olivier Soppera, France
Radhey Srivastava , USA
Vivek Srivastava, India
Theocharis C. Stamatatos , Greece
Athanasios Stavrakoudis , Greece
Darren Sun, Singapore
Arun Suneja , USA
Kamal Swami , USA
B.E. Kumara Swamy , India
Elad Tako , USA
Shoufeng Tang, China
Zhenwei Tang , China
Vijai Kumar Reddy Tangadanchu , USA
Franco Tassi, Italy
Alexander Tatarinov, Russia
Lorena Tavano, Italy
Tullia Tedeschi, Italy
Vinod Kumar Tiwari , India
Augusto C. Tome , Portugal
Fernanda Tonelli , Brazil
Naoki Toyooka , Japan
Andrea Trabocchi , Italy
Philippe Trens , France
Ekaterina Tsipis, Russia
Esteban P. Urriolabeitia , Spain

Toyonobu Usuki , Japan
Giuseppe Valacchi , Italy
Ganga Reddy Velma , USA
Marco Viccaro , Italy
Jaime Villaverde , Spain
Marc Visseaux , France
Balaga Viswanadham , India
Alessandro Volonterio , Italy
Zoran Vujcic , Serbia
Chun-Hua Wang , China
Leiming Wang , China
Carmen Wängler , Germany
Wieslaw Wiczkowski , Poland
Bryan M. Wong , USA
Frank Wuest, Canada
Yang Xu, USA
Dharmendra Kumar Yadav , Republic of
Korea
Maria C. Yebra-Biurrún , Spain
Dr Nagesh G Yernale, India
Tomokazu Yoshimura , Japan
Maryam Yousaf, China
Sedat Yurdakal , Turkey
Shin-ichi Yusa , Japan
Claudio Zaccone , Italy
Ronen Zangi, Spain
John CG Zhao , USA
Zhen Zhao, China
Antonio Zizzi , Italy
Mire Zloh , United Kingdom
Grigoris Zoidis , Greece
Deniz ŞAHİN , Turkey

Contents

Green Synthesis of New Pyrrolo [1,2-*a*] quinoxalines as Antiproliferative Agents in GPER-expressing Breast Cancer Cells

Gabriele Carullo , Sarah Mazzotta , Francesca Giordano, and Francesca Aiello 

Research Article (8 pages), Article ID 5596816, Volume 2021 (2021)

Research Article

Green Synthesis of New Pyrrolo [1,2-*a*] quinoxalines as Antiproliferative Agents in GPER-expressing Breast Cancer Cells

Gabriele Carullo ¹, Sarah Mazzotta ², Francesca Giordano,³ and Francesca Aiello ³

¹Department of Biotechnology, Chemistry and Pharmacy, DoE 2018-2022, University of Siena, Via Aldo Moro 2, Siena 53100, Italy

²Department of Pharmaceutical Sciences, University of Milan, Via Luigi Mangiagalli 25, Milano 20133, Italy

³Department of Pharmacy, Health and Nutritional Sciences, DoE 2018-2022, University of Calabria Edificio Polifunzionale, Arcavacata di Rende (CS) 87036, Italy

Correspondence should be addressed to Francesca Aiello; francesca.aiello@unical.it

Received 21 February 2021; Accepted 29 September 2021; Published 31 October 2021

Academic Editor: Lutfun Nahar

Copyright © 2021 Gabriele Carullo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

4,5-Dihydropyrrolo [1,2-*a*]quinoxalines are interesting druggable scaffolds, with multifaceted biological properties, including anticancer properties targeting the G protein-coupled estrogen receptor 1 (GPER). In this work, the synthesis and preliminary antiproliferative activity of a small set of new 4,5-dihydropyrrolo[1,2-*a*]quinoxalines (18-20) and pyrrolo[1,2-*a*]quinoxalines (21, 22) has been reported, inspired by known antiproliferative agents (G-1, G-15, and G-36). The synthesis of the pyrroloquinoxalinic core was employed following the Pictet-Spengler reaction, using the surfactant *p*-dodecylbenzene sulphonic acid (*p*-DBSA), as catalyst. It demonstrated efficiency in the catalysis of the 4-phenylpyrrole [1,2-*a*] quinoxaline type compound formation in mild solvents such as water, ethanol, and hydroalcoholic solutions. In addition, the reactions proceeded in a short time (between 15 and 120 minutes) at room temperature and with high yields. The *in vitro* MTT assays showed that the presence of isopropyl groups furnished promising antiproliferative compounds. Although, the acetyl group provided also antiproliferative effects, breaking down its responsibility in the GPER transactivation. Nevertheless, it is possible to conclude that the 4,5-dihydropyrrolo[1,2-*a*]quinoxalines remain a feasible scaffold to develop anticancer agents against GPER-expressing cells.

1. Introduction

Heterocycles are organic cyclic compounds in which one of the positions of the ring is a heteroatom. They represent the most important class of biologically active compounds, both from synthetic and natural sources [1]. Over the years, nitrogen heterocycles emerged as interesting scaffolds in organic and medicinal chemistry applications. In particular, they showed different biological properties, becoming innovative tools for the development of new therapeutic entities [2]. In this field, several aromatic and aliphatic nitrogen heterocycles have been reported as antibacterials [3], antivirals [4], anticancer [5, 6], anti-inflammatory [7, 8], and antihypertensive [9], among others [10]. Pyrrole is a five-membered aromatic ring, widely present in a variety of

biological contexts, as a xenobiotic or cofactor. In synthetic products, the pyrrole nucleus could be present as single/substituted/condensed rings, as linker between different moieties, although it can be directly associated with biological targets [11]. These peculiarities prompted synthetic chemists to explore not only efficient synthetic methods such as Paal-Knorr, Huisgen, and Hantzsch reactions but also innovative approaches including multicomponent and green processes [12, 13]. Pyrrole derivatives are privileged structures in medicinal chemistry due to the uncountable pharmacological profiles [14]. Among the activities, the anticancer one has been described for different types of pyrrole derivatives [14, 15]. The *N*-substituted pyrroles represent an extended family of derivatives, recognized as anticancer tools. In particular, a set of pyrrole-3-

carboxamide derivatives showed interesting antiproliferative effects in leukemia and pulmonary cell lines (such K562 and A549). The best compound 1 (Figure 1), derived from an intense structure-activity relationship (SAR) study, showed a low potency but high selectivity towards different tumor suppressors downstreams [16]. Furthermore, symmetrically substituted pyrroles were simply synthesized and evaluated as apoptotic agents in colorectal HCT116 and leukemic HL60 cells. The compounds, including 2 (Figure 1), induced time- and dose-dependent cell cycle arrest at the G_0/G_1 phase, although the corresponding pyrrolidines resulted more active [17]. Over the years, the search of new strategies for cancer therapy prompted us to investigate several pyrrole-based compounds, evaluating also new and efficient synthetic approaches [18–21]. The benzo-pyrrolo-oxazine derivative 3 (Figure 1) showed a limited activity in MDA-MB-231 triple negative breast cancer cells (TNBCs) [22]; the corresponding analogue 4, in which the biphenyl system, deprived of amide function, is appended in position 5, showed a better activity inducing apoptosis via poly (ADP-ribose) polymerase (PARP) cleavage [23]. In the field of proapoptotic agents, another class of pyrrole-based compounds is represented by pyrrolo-1,5-benzoxazepine 5 and pyrrolo-naphthoxazepine 6 (Figure 1). Moreover, 5 induced mitotic block and the onset of apoptosis in several cancer cell lines, while 6 resulted to be more druggable than 5 due to its pharmacokinetic properties and acted as a caspase 3-mediated apoptotic agent, interfering also with autophagic processes [24, 25]. Condensed pyrrole derivatives were also investigated by us focusing development of differently substituted pyrrolo[1,2-*a*]quinoxalines, extensively explored in breast cancer models. One of the first synthesized compounds 7 (Figure 1), consisting of a pyrroloquinoxaline skeleton embedded with a pyrazinylhydrazide moiety, displayed significant *in vivo* efficacy in mice xenograft models [26]. Recently, we described new analogues, in which the aromatic ring is directly connected to the pyrroloquinoxaline nucleus. Compound 8, assayed in MDA-MB-231 cell line, highlighted the formation of autophagic vacuoles, in line with compound 6 [27]. Similarly, compound 9 induced a pronounced apoptosis in SKBR3 cells, compared to MCF-7, emphasizing the role of this type of compound in the most aggressive TNBC (Figure 1) [28]. Based on these promising data, in this work, we reported the synthesis and preliminary antiproliferative activity of a small set of new 4,5-dihydropyrrolo[1,2-*a*]quinoxalines 18–20 and pyrrolo[1,2-*a*]quinoxalines 21, 22, inspired by known antiproliferative agents (G-1, G-15, and G-36) (Figure 1). G-1, chemically known as 1-((3*a*S,4*R*,9*b*R)-4-(6-bromobenzo[*d*][1,3]dioxol-5-yl)-3*a*,4,5,9*b*-tetrahydro-3*H*-cyclopenta[*c*]quinolin-8-yl)ethan-1-one, a potent and selective GPER agonist ($K_i = 11$ nM, $EC_{50} = 2$ nM), displays no activity at $ER\alpha$ and $ER\beta$ at concentrations up to $10\ \mu\text{M}$. It also increases intracellular calcium levels and inhibits the migration of SKBR3 and MCF-7 cells in response to chemoattractants (IC_{50} values are 0.7 and 1.6 nM, respectively) *in vitro*. G-15 is a high affinity and selective GPER antagonist with K_i of 20 nM. The compounds described here derived from two building blocks 16 and

17. These precursors are decorated with acetyl and isopropyl moieties, respectively, also found in 5, 6, 11, and other antiproliferative agents. The pending phenyl ring was modified with methylenedioxy or vanillic portions, as in compounds 8 and 9 (Figure 1).

2. Materials and Methods

2.1. Chemistry. All reagents were purchased from Merck and used without further purification. Solvents were dried and distilled according to conventional procedures [29]. Anhydrous reactions were carried out under argon atmosphere, monitored by thin layer chromatography (TLC) on silica gel plates (Merck 60F254, 0.2 mm) and visualized by UV light at 254 and 366 nm of wavelength. Organic solutions were dried over anhydrous Na_2SO_4 and evaporated on a rotary evaporator under reduced pressure. Final compounds were purified by flash chromatography columns on silica gel (Merck, 60, 230–400 mesh, 0.040–0.063 mm). Melting points were obtained by a Gallenkamp21374 apparatus and were uncorrected. $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ spectra were recorded on a Bruker 300 MHz spectrometer. Chemical shifts (δ) were reported in ppm, using tetramethylsilane (TMS) as the internal reference standard. Coupling constants were reported as J values in Hertz (Hz), and the number of protons is indicated parenthetically. Mass spectra data were determined after electron impact ionization at 70 eV on the HP 5973MS spectrometer. Elemental analyses were performed on LECO TruSpec CHNS Microelemental system (St. Joseph, MI, USA). The purity of the final compounds was evaluated by C, H, N analysis, and it was confirmed to be $\geq 95\%$. Yields refer to purified products and are not optimized.

2.1.1. Synthesis of *N*-(5-Acetyl-2-nitrophenyl)acetamide (11). To a cooled mixture (0–5°C) of fuming nitric acid (0.5 mL) and acetic anhydride (1 mL), the commercially available *N*-(3-acetylphenyl)acetamide 10 was added. The reaction was stirred for 10 min, and then, ice was added to the mixture. The obtained solution was neutralized with aqueous K_2CO_3 and extracted with CHCl_3 . The organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The pure compound 11 was isolated by flash chromatography using chloroform:diethyl ether (1:1) as eluent. Yellow crystals (18% yield); m.p. 121°C. $^1\text{H-NMR}$ (CDCl_3) δ : 10.21 (bs, 1H), 9.28 (d, 1H, $J = 1.8$ Hz), 8.20 (d, 1H, $J = 8.8$ Hz), 7.65 (dd, $J = 1.9$ Hz $J = 8.8$ Hz), 2.60 (s, 3H), and 2.25 (s, 3H). MS (EI): m/z 222 [M] $^+$.

2.1.2. Synthesis of 1-(4-Nitro-3-(1*H*-pyrrol-1-yl)phenyl)ethan-1-one (12). Compound 11 (3.15 mmol) was suspended in 6*N* aqueous HCl (10 mL), and the mixture was heated at 120°C for 4 h. Then, the reaction was cooled to 0°C and neutralized with aqueous NaOH 50% m/V. The compound 1-(3-amino-4-nitrophenyl)ethan-1-one was obtained after precipitation as red crystals and used without further purification (MS (EI): m/z 180 [M] $^+$). This intermediate




FIGURE 1: Design of new pyrrolo-[1,2-*a*]quinoxalines.

(2.77 mmol) was added to a hot solution of 4-chloropyridine hydrochloride (2.77 mmol) and 2,5-dimethoxytetrahydrofuran (3.32 mmol) in 1,4-dioxane (7 mL). The resulting mixture was stirred at 150°C for 1 h, cooled to room temperature, and filtered using Celite®. The pure compound 12 was isolated by flash chromatography using *n*-hexane : ethyl acetate (3 : 1) as eluent. Orange oil (89% yield). ¹H-NMR (CDCl₃) δ: 8.04–8.02 (m, 1H), 8.00 (d, 1H, *J* = 2.0 Hz), 7.91 (dd, 1H, *J* = 0.55 Hz, *J* = 8.2 Hz), 6.83 (t, 2H, *J* = 2.1 Hz), 6.40 (t, 2H, *J* = 2.2 Hz), and 2.70 (s, 3H). MS (EI): *m/z* 230 [M]⁺.

2.1.3. Synthesis of 2-Bromo-4-isopropyl-1-nitrobenzene (14). To a cold solution (0°C) of dry toluene (20 mL), 2-bromo-4-isopropylaniline (13, 2.33 mmol) was added. This mixture was stirred for 10 min, and then, *m*-chloroperbenzoic acid (*m*-CPBA, 16.9 mmol) was added. The resulting solution was refluxed for 24 h, cooled to room temperature, filtered in vacuum, and washed with fresh toluene. The liquid residue was diluted with diethyl ether and extracted with 10% aqueous NaOH. The organic layer was dried over Na₂SO₄, filtered, and evaporated. The pure compound 14 was isolated

by flash chromatography using *n*-hexane/dichloromethane (4 : 1) as eluent. Yellow oil. 70% yield. Spectroscopic data agree with those published [30].

2.1.4. 1-(5-Isopropyl-2-nitrophenyl)-1H-pyrrole (15). Acetonitrile (24 mL) was added to a mixture of 14 (1.64 mmol), pyrrole (8.2 mmol), potassium iodide (1.97 mmol), copper powder (1.64 mmol), and cesium carbonate (3.28 mmol). The resulting suspension was refluxed for 48 h, cooled to room temperature, and filtered in vacuum. The residue was dried, and the pure compound 15 was isolated by flash chromatography using petroleum ether/chloroform (3 : 1). Yellow oil (43% yield). ¹H-NMR (CDCl₃) δ: 7.83 (d, 1H, *J* = 8.0 Hz), 7.34 (d, 1H, *J* = 1.8 Hz), 7.31 (s, 1H), 6.81 (t, 2H, *J* = 2.0 Hz), 6.38 (t, 2H, *J* = 2.1 Hz), 3.10–2.98 (m, 1H), and 1.35 (s, 6H). MS (EI) *m/z*: 230 [M]⁺.

2.1.5. General Procedure for the Synthesis of Anilines (16-17). Compound 12 or 15 (2.47 mmol) was diluted in ethanol 96% (16.5 mL) and heated at 55°C. Then, iron powder

(9.91 mmol) and aqueous solution (2 mL) of ammonium chloride (9.91 mmol) were added. The mixture was stirred at the same temperature for 1 h, cooled to room temperature, and filtered using Celite®. The residue was basified to pH 8 by adding a saturated NaHCO₃ solution and extracted with ethyl acetate (3 × 30 mL). The organic layer was then dried, filtered, evaporated, and used without purification.

2.1.6. General Procedure for the Synthesis of Pyrrolo[1,2-*a*]quinoxalines (18–21). To a well-stirred solution of *p*-DBSA (0.0291 mmol) in ethanol 96% (2 mL), the aniline (16 or 17, 0.291 mmol) and the corresponding aldehyde (0.349 mmol) were added. The mixture was stirred for 15 min at room temperature, and the solvent was evaporated to dryness. The residue was diluted with ethyl acetate, washed with saturated NaHCO₃ aqueous solution, and then with brine. The organic layer was dried over Na₂SO₄ and concentrated in vacuum. The pure compounds were obtained by flash chromatography using *n*-hexane/ethyl acetate (6:1 to 2:1) as eluent.

1-(4-(6-Bromobenzo[*d*][1,3]dioxol-5-yl)-4,5-dihydropyrrolo[1,2-*a*]quinoxalin-8-yl)ethan-1-one (18). White solid (43% yield); m.p. 225°C. ¹H-NMR (300 MHz, acetone-*d*₆): δ 8.00 (s, 1H), 7.54 (dd, 1H, *J* = 1.8 Hz, *J* = 8.3 Hz), 7.47–7.43 (m, 2H), 6.99 (s, 1H), 6.85 (d, 1H, *J* = 8.4 Hz), 6.63 (s, 1H), 6.17 (t, 1H, *J* = 3.3 Hz), 5.99 (s, 1H), 5.90 (d, 2H, *J* = 1.8 Hz), 5.70 (bs, 1H), 3.50 (s, 3H). ¹³C-NMR (75 MHz, acetone-*d*₆): δ 193.9, 147.4, 147.1, 139.4, 134.2, 126.0, 125.2, 122.6, 114.7, 114.2, 113.8, 113.5, 113.3, 111.6, 108.2, 107.4, 105.2, 101.4, 53.0, 24.4. MS (EI) *m/z*: 410 [M]⁺. Anal. calcd. for C₂₀H₁₅BrN₂O₃: C 58.41, H 3.68, N 6.81% found C 58.40, H 3.65, N 6.83%.

4-(6-Bromobenzo[*d*][1,3]dioxol-5-yl)-8-isopropyl-4,5-dihydropyrrolo[1,2-*a*]quinoxaline (19). Amber oil (56% yield). ¹H-NMR (300 MHz, CDCl₃): δ 7.22–7.20 m (1H), 7.01 (s, 1H), 6.85 (d, 1H, *J* = 7.5 Hz), 6.75 (s, 1H), 6.67 (d, 1H, *J* = 8.2 Hz), 6.30 (t, 1H, *J* = 3.3 Hz), 6.09 (d, 1H, *J* = 6.7 Hz), 5.95 (s, 2H), 5.70 (bs, 1H), 4.28 (bs, 1H), 2.95–2.82 (m, 1H), 1.30 (s, 6H). ¹³C-NMR (75 MHz, CDCl₃): δ 147.8, 138.0, 136.0, 135.0, 133.0, 131.0, 130.0, 129.0, 128.1, 122.8, 115.2, 115.0, 112.9, 112.3, 110.1, 110.0, 105.2, 33.4, 23.1. MS (EI) *m/z*: 410 [M]⁺. Anal. calcd. for C₂₁H₁₉BrN₂O₂: C 61.33, H 4.66, N 6.81% found C 61.35, H 3.62, N 6.80%.

4-(8-Isopropyl-4,5-dihydropyrrolo[1,2-*a*]quinoxalin-4-yl)-2-methoxyphenol (20). Yellow solid (42% yield); m.p. 121–122°C. ¹H-NMR (300 MHz, CDCl₃): δ 7.32–7.21 (m, 3H), 7.10 (d, 1H, *J* = 1.7 Hz) 7.05–6.94 (m, 2H), 6.92–6.85 (m, 1H), 6.76 (s, 1H), 6.70–6.27 (m, 2H), 6.27 (t, 1H, *J* = 3.1 Hz), 5.67 (bs, 1H), 5.60 (bs, 1H), 5.44 (s, 1H), 3.90 (s, 3H), 3.00–2.82 (m, 1H), 1.35 (s, 6H); ¹³C-NMR (75 MHz, CDCl₃): δ 145.8, 144.7, 139.5, 133.3, 132.2, 129.7, 124.5, 121.5, 120.3, 114.3, 113.3, 113.0, 111.9, 109.3, 109.0, 104.7, 55.3, 55.0, 33.6, 23.3. MS (EI) *m/z*: 332 [M]⁺. Anal. calcd. for C₂₁H₂₂N₂O₂: C 75.42, H 6.63, N 8.38% found C 75.50, H 6.60, N 8.35%.

1-(4-(4-Hydroxy-3-methoxyphenyl)pyrrolo[1,2-*a*]quinoxalin-8-yl)ethan-1-one (21). Yellow solid (95% yield); m.p. 222°C. ¹H-NMR (300 MHz, CDCl₃): δ 8.50 (s, 1H), 8.15–7.99 (m, 3H),

7.64–7.59 (m, 2H), 7.13–7.05 (m, 2H), 6.94 (dd, 1H, *J* = 2.7 Hz, *J* = 7.0 Hz), 6.20 (bs, 1H), 4.00 (s, 3H), 2.80 (s, 3H); ¹³C-NMR (75 MHz, CDCl₃): δ 196.9, 155.9, 147.9, 146.8, 139.6, 134.8, 130.1, 129.8, 126.9, 125.2, 122.5, 115.8, 114.5, 114.3, 113.7, 111.2, 110.1, 56.1, 26.7. MS (EI) *m/z*: 332 [M]⁺. Anal. calcd. for C₂₀H₁₆N₂O₃: C 72.28, H 4.85, N 8.43% found C 75.20, H 4.88, N 8.46%.

1-(4-Amino-3-(1H-pyrrol-1-yl)phenyl)ethan-1-one (16). Orange oil (81% yield). ¹H-NMR (CDCl₃) δ: 7.84 (d, 1H, *J* = 2.0 Hz), 7.81 (d, 1H, *J* = 1.9 Hz), 7.79 (d, 1H, *J* = 1.8 Hz), 6.84 (t, 2H, *J* = 2.0 Hz), 6.38 (t, 2H, *J* = 2.1 Hz), 4.20 (bs, 2H), and 2.50 (s, 3H). MS (EI) *m/z*: 200 [M]⁺.

4-Isopropyl-2-(1H-pyrrol-1-yl)aniline (17). Yellow solid (70% yield). ¹H-NMR (300 MHz, CDCl₃) δ: 6.95–6.85 (m, 2H), 6.73 (t, 2H, *J* = 3.9 Hz), 6.61 (d, 1H, *J* = 8.5 Hz), 6.23 (t, 2H, *J* = 3.8 Hz), 3.40 (bs, 2H), 2.70 (m, 1H), 1.15 (s, 3H), and 1.10 (s, 3H).

2.2. Biological Evaluation

2.2.1. Reagents. The following components were obtained from the respective companies, with their addresses in brackets. DMEM/F-12, Dulbecco's modified Eagle's medium, RPMI medium, L-Glutamine, penicillin/streptomycin, Dulbecco's Phosphate Buffer Saline were purchased from by Invitrogen (Carlsbad, CA, USA). MTT, dimethyl sulphoxide, and propidium iodide are from Sigma (Milan, Italy).

2.2.2. Cell Cultures. MCF-7 and SKBR3 breast cancer cells were obtained from the American Type Culture Collection (ATCC) (Manassas, VA). MCF-7 cells were cultured in DMEM-F12 containing 5% fetal bovine serum, 1% L-glutamine, and 1 mg/ml penicillin–streptomycin. SKBR3 cells were maintained in complete RPMI supplemented with 10% fetal bovine serum, 1% L-glutamine, and 1 mg/ml penicillin–streptomycin.

2.2.3. DNA Flow Cytometry. To determine cell cycle distribution analysis, cells were harvested by trypsinization, fixed, and stained with propidium iodide (100 g/mL) after treatment with RNase A (20 g/mL). The DNA content was measured using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA), and the data were acquired using Cell Quest software. Cell cycle profiles were determined using ModFit LT.

3. Results and Discussion

3.1. Chemistry. The synthesized compounds, characterized by a 4,5-dihydropyrrolo[1,2-*a*]quinoxaline scaffold (18, 19) and a pyrrolo[1,2-*a*]quinoxaline scaffold (20, 21) were synthesized using the Pictet–Spengler condensation. For the synthesis of anilines 16 and 17, two different synthetic pathways were employed (Figure 2). In the case of 16, the commercially available 3-acetamido acetophenone (10) was nitrated in the presence of the nitrating couple fuming nitric




FIGURE 2: Synthesis of compounds 18–21.

acid/acetic anhydride, furnishing a mixture of regioisomers from which the compound 11 was isolated for further modifications. The acetamido function of 11 was hydrolyzed in acidic conditions (6N HCl) to obtain the aniline derivative that was available for the Clauson–Kass reaction to obtain the pyrrole one 12. Then, 12 was reduced in the presence of iron powder and ammonium chloride in ethanol to afford the final aniline intermediate 16. On the other hand, for the synthesis of 17, 2-bromo-4-isopropylaniline 13 was first oxidized in the presence of *m*-CPBA in toluene. The intermediate 14 was then reacted with pyrrole under Ullmann conditions in the presence of copper powder, potassium iodide, and cesium carbonate. The nitro group of compound 15 was then reduced to aniline 17 in the same conditions described for 16. Both derivatives 16 and 17 were subjected to the Pictet–Spengler reaction with the aim of obtaining the final compounds 18–21 (Figure 2). The copy of original GCMS and NMR spectra of final compound 18–21 are reported in Figures S1–S8 in Supplementary Materials. The Pictet–Spengler reaction was born in 1911 from two chemists Amé Pictet and Theodor Spengler who synthesized, for the first time, tetrahydroisoquinolines. This method consists in the condensation of a β -arylenylamine with an aldehyde or a ketone in acid catalysis. The mechanism involves the initial protonation of the carbonyl oxygen by the acid; this intermediate was then subjected to the nucleophilic substitution by the amine, furnishing a Schiff base with the contemporary release of a water molecule. The iminic intermediate therefore undergoes a 6-endo-trig cyclization with loss of aromaticity. The final deprotonation restores the aromaticity and provides the

tetrahydroisoquinoline core. Some variants involve the use of Lewis acids as catalysts. Generally, this procedure involved harmful organic solvents such as tetrahydrofuran, acetonitrile, and toxic catalysts such as aluminium chloride, with low yields. Based on recent studies that use surfactants as catalysts for chemical reactions, *p*-dodecylbenzenesulfonic acid (*p*-DBSA) was evaluated as a green and potential catalyst for the Pictet–Spengler reaction. It demonstrated efficiency in the catalysis of the 4-phenylpyrrole [1,2-*a*]quinoxaline type compound formation in mild solvents such as water, ethanol, and hydroalcoholic solutions. In addition, the reactions proceeded in short time (between 15 and 120 minutes) at room temperature and with high yields. In this work, different arylaldehydes such 6-bromopiperonal and vanillin were used to introduce the pursued chemical diversity by different types of substituents. *p*-DBSA was used as an efficient catalyst providing compounds in short time (from 30 to 90 minutes) in ethanol as solvent.

3.2. Biological Evaluation. First, we investigated the effects of four synthetic compounds on breast cancer cell viability, by using SKBR3 cells (GPER⁺, ER α ⁻, and ER β ⁻) and MCF-7 cells (GPER⁺, ER α ⁺, and ER β ⁺). These cells were treated with 1 μ M of compounds 18–21 for 24 and 48 h, by using the MTT assay. The selected dose was used to be in line with our previous experiments [28]. As shown in Figure 3, a significant decreasing in cell viability was observed after 24 h and 48 h of treatment, respectively, with compounds 19 and 20 in SKBR3 cells.




FIGURE 3: Effects compounds on breast cancer growth. MTT growth assays in MCF-7 and SKBR3 cells were treated with $1 \mu\text{M}$ of 18, 19, 20, and 21 compounds for 24 and 48 hours. Untreated cells are denoted with control (C). Cell proliferation is the representative of three different experiments, each performed in triplicate.





FIGURE 4: Effects of compounds 18, 19, 20, 21, and G-1 on cell cycle distribution in breast cancer cells. (a) MCF-7 and SKBR3 cells treated with $1 \mu\text{M}$ of compounds as indicated for 48 h, stained with propidium iodide (PI), and analyzed on a FACSscan flow cytometer. (b) Quantitative analysis of percentage gated cells at G1, S, and G2/M phases were shown.

To determine whether the cell growth inhibition induced by the compounds was a consequence of cell cycle perturbations, under the same experimental conditions, the flow cytometric cell cycle analysis in MCF-7 and SKBR3 breast cancer cells was performed. The results obtained showed an increase in the G1 phase and a concomitant reduction of cell population in S-phase, compared to untreated cells, especially in SKBR3 cells treated with compounds 19 and 20. Otherwise, in MCF-7 cells was not observed any change (Figure 4), probably involving a GPER-mediated activity.

GPER is known to mediate rapid nongenomic signals of estrogens, modulating their responsiveness and development and/or progression of ER⁻ breast cancers. Numerous studies demonstrated that activation of GPER by its specific synthetic agonist G-1 results in cell cycle arrest and proliferation inhibition of ER α ⁺ breast cancer [31], endothelial cells [32], prostate [33], and ovarian [34] cancer cells. Different studies suggest that GPER could be an excellent new therapeutic target for the treatment of ER⁻ breast cancer [35]. Our preliminary results demonstrated that compounds 19 and 20 could represent the most promising GPER ligands endowing with specific anticancer activity in SKBR3 cells. From the chemical point of view, 19 shows the 6-bromobenzodioxolyl moiety typical of both GPER antagonists G-15 and G-36 and the agonist G-1. 20 lacks this motif to show instead a vanillyl one that could be featured as an opened form of dioxole. Both are decorated on C8 position with an isopropyl group, present in the GPER antagonist G-36.

4. Conclusions

Pyrrole-based compounds showed to be harmful pharmaceutical agents, able to interfere with different biological systems. Diversified derivatives demonstrated suitable anticancer properties. In this study, the small number of compounds does not allow to perform a deep SAR study. Overall, the pyrroloquinoxaline scaffold is demonstrated to be an interesting tool for the development of new antiproliferative agents. The presence of isopropyl groups furnished good antiproliferative compounds in line with the better activity exerted by G-36 compared to G-15. Although, the acetyl group provided also antiproliferative effects, breaking down its responsibility in the GPER transactivation. Nevertheless, it is possible to conclude that the 4,5-dihydropyrrolo[1,2-*a*]quinoxalines remains a feasible scaffold to develop anticancer agents against GPER-expressing cells.

Data Availability

The data used to support the findings of this study are included within the article.

Disclosure

Gabriele Carullo and Sarah Mazzotta are the co-first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors from Department of Pharmacy, Health and Nutritional Sciences, University of Calabria and authors from Department of Biotechnology, Chemistry and Pharmacy, University of Siena wish to thank Ministero dell'Isruzione, dell'Università e della Ricerca for the grant "Dipartimento di Eccellenza 2018–2022" (L. 232/2016).

Supplementary Materials

Copies of MS(EI), ¹H-NMR, and ¹³C-NMR spectra (S1–S8). (*Supplementary Materials*)

References

- [1] R. Dua, S. Shrivastava, S. K. Sonwane, and S. K. Srivastava, "Pharmacological significance of synthetic heterocycles scaffold: a review," *Advances in Biological Research*, vol. 5, pp. 120–144, 2011.
- [2] N. Kerru, L. Gummidi, S. Maddila, K. K. Gangu, and S. B. Jonnalagadda, "A review on recent advances in nitrogen-containing molecules and their biological applications," *Molecules*, vol. 25, 2020.
- [3] S. Mazzotta, T. Cebrero-Cangueiro, L. Frattaruolo et al., "Exploration of piperazine-derived thioureas as antibacterial and anti-inflammatory agents. In vitro evaluation against clinical isolates of colistin-resistant *Acinetobacter baumannii*," *Bioorganic and Medicinal Chemistry Letters*, vol. 30, no. 18, Article ID 127411, 2020.
- [4] S. Mazzotta, J. A. Marrugal-Lorenzo, M. Vega-Holm et al., "Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents," *European Journal of Medicinal Chemistry*, vol. 185, Article ID 111840, 2020.
- [5] A. P. Saraswati, N. Relitti, M. Brindisi et al., "Spiroindoline-capped selective HDAC6 inhibitors: design, synthesis, structural analysis, and biological evaluation," *ACS Medicinal Chemistry Letters*, vol. 11, no. 11, pp. 2268–2276, 2020.
- [6] N. Relitti, A. P. Saraswati, G. Chemi et al., "Novel quinolone-based potent and selective HDAC6 inhibitors: synthesis, molecular modeling studies and biological investigation," *European Journal of Medicinal Chemistry*, vol. 90, Article ID 112998, 2020.
- [7] S. Mazzotta, L. Frattaruolo, M. Brindisi et al., "3-Aminoalkylated indoles: unexplored green products acting as anti-inflammatory agents," *Future Medicinal Chemistry*, vol. 12, no. 1, pp. 5–17, 2020.
- [8] S. Shafi, M. Mahboob Alam, N. Mulakayala et al., "Synthesis of novel 2-mercapto benzothiazole and 1,2,3-triazole based bis-heterocycles: their anti-inflammatory and anti-nociceptive activities," *European Journal of Medicinal Chemistry*, vol. 49, pp. 324–333, 2012.
- [9] G. Grover, R. Nath, R. Bhatia, and M. J. Akhtar, "Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants," *Bioorganic and Medicinal Chemistry*, vol. 28, no. 15, Article ID 115585, 2020.
- [10] M. M. Heravi and V. Zadsirjan, "Prescribed drugs containing nitrogen heterocycles: an overview," *RSC Advances*, vol. 10, no. 72, pp. 44247–44311, 2020.
- [11] S. S. Gholap, "Pyrrole: an emerging scaffold for construction of valuable therapeutic agents," *European Journal of Medicinal Chemistry*, vol. 110, pp. 13–31, 2016.

- [12] D. D. Xuan, "Recent progress in the synthesis of pyrroles," *Current Organic Chemistry*, vol. 24, no. 6, pp. 622–657, 2020.
- [13] A. Sharma and P. Piplani, "Microwave-activated synthesis of pyrroles: a short review," *Journal of Heterocyclic Chemistry*, vol. 54, no. 1, pp. 27–34, 2017.
- [14] S. Ahmad, O. Alam, M. J. Naim, M. Shaquiquzzaman, M. M. Alam, and M. Iqbal, "Pyrrole: an insight into recent pharmacological advances with structure activity relationship," *Elsevier Masson SAS*, vol. 157, 2018.
- [15] H. Kuznietsova, N. Dziubenko, I. Byelinska et al., "Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety," *Journal of Drug Targeting*, vol. 28, no. 5, pp. 547–563, 2020.
- [16] Q. Zhou, L. Jia, F. Du et al., "Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents," *New Journal of Chemistry*, vol. 44, no. 6, pp. 2247–2255, 2020.
- [17] J. Ji, F. Sajjad, Q. You et al., "Synthesis and biological evaluation of substituted pyrrolidines and pyrroles as potential anticancer agents," *Archiv der Pharmazie*, vol. 353, Article ID e2000136, 2020.
- [18] F. Aiello, A. Garofalo, and F. Grande, "Direct cyclization of ortho-(1H-pyrrol-1-yl)aryl and heteroaryl carboxylic acids into fused pyrrolizinones," *Tetrahedron Letters*, vol. 51, no. 50, pp. 6635–6636, 2010.
- [19] F. Aiello, A. Garofalo, and F. Grande, "Convenient synthesis of fluorazone derivatives by one-pot pyrrolation/cyclization of anthranilic acids," *Tetrahedron Letters*, vol. 52, no. 44, pp. 5824–5826, 2011.
- [20] F. Aiello, A. Garofalo, and F. Grande, "Efficient synthesis of 9H-pyrrolo[1,2-a]indol-9-one derivatives based on active manganese dioxide promoted intramolecular cyclization," *Tetrahedron*, vol. 66, no. 1, pp. 274–277, 2010.
- [21] F. Grande, A. Brizzi, A. Garofalo, and F. Aiello, "Active manganese dioxide promoted cyclization of ortho-(1H-pyrrol-1-yl)aryl and heteroaryl carboxylic acids to 5H-pyrrolo [1,2-a][3,1]benzoxazin-5-one derivatives," *Tetrahedron*, vol. 69, no. 47, pp. 9951–9956, 2013.
- [22] M. Badolato, G. Carullo, F. Aiello, and A. Garofalo, "Synthesis and experimental validation of new PDI inhibitors with antiproliferative activity," *Journal of Chemistry*, vol. 2017, 2017.
- [23] M. Badolato, G. Carullo, B. Armentano, S. Panza, R. Malivindi, and F. Aiello, "Synthesis and anti-proliferative activity of a small library of 7-substituted 5H-pyrrole [1,2-a][3,1]benzoxazin-5-one derivatives," *Bioorganic and Medicinal Chemistry Letters*, vol. 27, no. 14, pp. 3092–3095, 2017.
- [24] L. Greene, S. Butini, G. Campiani, D. Williams, and D. Zisterer, "Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines," *Journal of Cancer*, vol. 7, no. 15, pp. 2367–2377, 2016.
- [25] M. Brindisi, C. Olivieri, G. Alfano et al., "Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents," *European Journal of Medicinal Chemistry*, vol. 162, pp. 290–320, 2019.
- [26] F. Grande, F. Aiello, O. D. Grazia, A. Brizzi, A. Garofalo, and N. Neamati, "Synthesis and antitumor activities of a series of novel quinoxalinhydrazides," *Bioorganic and Medicinal Chemistry*, vol. 15, no. 1, pp. 288–294, 2007.
- [27] M. Perri, F. Aiello, E. Cione et al., "Investigation of TNBC in vitro antiproliferative effects of versatile pyrrolo[1,2-a]quinoxaline compounds," *Frontiers in Molecular Biosciences*, vol. 6, pp. 1–5, 2019.
- [28] F. Aiello, G. Carullo, F. Giordano et al., "Identification of breast cancer inhibitors specific for G protein-coupled estrogen receptor (GPER)-Expressing cells," *ChemMedChem*, vol. 12, no. 16, pp. 1279–1285, 2017.
- [29] E. D. Morgan, "Vogel's textbook of practical organic chemistry. 5th edn," *Endeavour*, vol. 14, no. 3, p. 148, 1990.
- [30] C. C. Cheng, X. Huang, G. W. Shipps et al., "Pyridine carboxamides: potent palm site inhibitors of HCV NS5B polymerase," *ACS Medicinal Chemistry Letters*, vol. 1, no. 9, pp. 466–471, 2010.
- [31] E. A. Ariazi, E. Brailoiu, S. Yerrum et al., "The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells," *Cancer Research*, vol. 70, no. 3, pp. 1184–1194, 2010.
- [32] A. Holm, B. Baldetorp, B. Olde, L. M. F. Leeb-Lundberg, and B.-O. Nilsson, "The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle," *Journal of Vascular Research*, vol. 48, no. 4, pp. 327–335, 2011.
- [33] Q. K. Y. Chan, H.-M. Lam, C.-F. Ng et al., "Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G2 cell-cycle arrest," *Cell Death and Differentiation*, vol. 17, no. 9, pp. 1511–1523, 2010.
- [34] X. Lv and C. Wang, "G-1: new potential therapeutic option for ovarian cancer," *Cancer Cell Microenvironment*, vol. 1, pp. 17–19, 2014.
- [35] J.-Q. Chen and J. Russo, "ER α -negative and triple negative breast cancer: molecular features and potential therapeutic approaches," *Biochimica et Biophysica Acta (BBA)—Reviews on Cancer*, vol. 1796, no. 2, pp. 162–175, 2009.